Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Status:
Completed
Trial end date:
2016-12-20
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The
purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in
patients at significant risk for recurrence following complete resection of primary GIST.